30/10/2017 Louise News, Immuno-Oncology
Aquila's immunology, IO and specialist Histology expertise broadens Concept’s range of integrated drug discovery and development services. Both companies share the same approach to client service and interaction, focusing on close collaboration with clients to offer a bespoke service tailored to their needs and requirements. This is a very exciting and important acquisition for both Aquila and Concept, with the aim of driving growth and development for all.
Please click here for the full press release.